更新于：2024-11-04
B·R·A·H·M·S GmbH
更新于：2024-11-04
概览
关联
IDEntifying pAtients With Suspicion of Infection in the ED Who Have Low Disease Severity Using Midregional Proadrenomedullin (MR-proADM) - Pivotal Study
PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs
Chromogranin A as Surveillance Biomarker in Patients With cARcinoids (The CASPAR Study)
100 项与 B·R·A·H·M·S GmbH 相关的临床结果
登录后查看更多信息
登录后查看更多信息
2023-12-31Journal of medical economics
Benefits of MR-proADM-guided decision-making in the emergency department: clinical and economic evaluation in Italy, Germany, Spain, and the UK
Article
作者: Porta, Camilla ; Monterosso, Filippo ; Pradelli, Lorenzo ; Povero, Massimiliano ; Houshmand, Hirad ; Pinciroli, Matteo ; Kirsch, Stefan ; Schuetze, Tabea ; Del Castillo, Juan González
AIM:
In a randomized control trial mid-regional proadrenomedullin (MR-proADM)-guided decision-making has been proven to safely reduce hospital admissions based on an accurate assessment of disease severity in the Emergency Department (ED). This study aimed to assess the impact of a MR-proADM-Guided Triage (MR-GT) versus standard Hospital Triage (HT) on clinical and economic outcomes in ED patients with suspected infection in Spain, Italy, Germany, and the UK, using Patient-Level Data (PLD) from two observational studies.
METHODS:
PLD was collected from patients enrolled at a Spanish hospital during two observational studies. Logistic regression was used to identify predictors of hospitalization. A patient-level simulation model was subsequently developed to evaluate the clinical and economic impact of MR-GT versus HT using results from the statistical analysis and country-specific cost data from the published literature. Probabilistic and deterministic sensitivity analyses were carried out.
RESULTS:
Four hundred seventy-three patients were enrolled in this study. MR-proADM had the strongest association with hospital admission, followed by age and National Early Warning Score (NEWS). In the simulation model, MR-GT was associated with an overall reduction in hospitalization relative to HT, equal to 22.6 percentage points (40.9 vs. 63.5%). In addition, the use of MR-GT would reduce the total hospital cost per patient presenting to the ED with suspected infection by roughly 30%, with a mean cost saving per patient of €626, €1,484, €1,154, and £1,113 in Spain, Italy, Germany, and the UK, respectively. The robustness of these findings was confirmed by sensitivity analyses.
LIMITATIONS:
The statistical analyses were not performed on the same population simulated in the model. Clinical input parameters were assumed to be the same for all countries.
CONCLUSIONS:
MR-proADM showed to be the main predictor of hospitalization. An MR-proADM decision algorithm provides cost savings in Spain, Italy, Germany, and the UK.
2019-12-01Critical care (London, England)
Biomarkers to guide antibiotic timing and administration in infected patients presenting to the emergency department
Letter
作者: Del Castillo, Juan Gonzalez ; Tegnér, Lena ; Rosenqvist, Mari ; Melander, Olle ; Peyman, Marjaneh ; Saeed, Kordo ; Wilson, Darius Cameron ; Bengtsson-Toni, Maria
2019-12-01Critical care (London, England)1区 · 医学
Correction to: The early identification of disease progression in patients with suspected infection presenting to the emergency department: a multi-centre derivation and validation study
1区 · 医学
ArticleOA
作者: Limper, Maarten ; Rood, Pleunie P M ; Bloos, Frank ; Hausfater, Pierre ; Callejo, Carlota Clemente ; Amin, Deveendra ; White, Graham ; Minieri, Marilena ; Wilson, Darius Cameron ; Claessens, Yann-Erick ; Brandi, Antonella ; Macchi, Marc-Alexis ; Dryden, Matthew ; Patka, Peter ; Bernardini, Sergio ; Saeed, Kordo ; Yañez, María Cecilia ; Beau, Nathalie ; Schuetz, Philipp ; Kutz, Alexander ; Chan, Louisa ; Legramante, Jacopo M ; Cortes, Nicholas ; van Gorp, Eric C M ; Mueller, Beat ; Melander, Olle ; Del Castillo, Juan Gonzalez ; van der Does, Yuri ; Rosenqvist, Mari
In the publication of this article [1], there are two errors in contributing author affiliations. This has now been included in this correction article.
2023-04-11
·动脉网
100 项与 B·R·A·H·M·S GmbH 相关的药物交易
登录后查看更多信息
100 项与 B·R·A·H·M·S GmbH 相关的转化医学
登录后查看更多信息
组织架构
使用我们的机构树数据加速您的研究。
登录
或
管线布局
2024年12月23日管线快照
无数据报导
登录后保持更新
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
营收
使用 Synapse 探索超过 36 万个组织的财务状况。
登录
或
科研基金(NIH)
访问超过 200 万项资助和基金信息，以提升您的研究之旅。
登录
或
投资
深入了解从初创企业到成熟企业的最新公司投资动态。
登录
或
融资
发掘融资趋势以验证和推进您的投资机会。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用